Welcome to our dedicated page for Cannapharmarx news (Ticker: CPMD), a resource for investors and traders seeking the latest updates and insights on Cannapharmarx stock.
CannaPharmaRX, Inc. reports developments in cannabis cultivation and international export operations. The company operates cannabis production activities in Alberta and has described shipments, purchase orders, harvest activity and distribution relationships tied to medical cannabis markets including Israel and Germany.
Recurring updates for CPMD include facility utilization, cannabis strain development, product quality and THC-related pricing, inventory preparation, export licensing, quarterly financial results and balance-sheet initiatives. Company news also covers Canadian regulatory matters, including continuous-disclosure issues with the British Columbia Securities Commission.
CannaPharmaRx, Inc. (OTC PINK:CPMD) has entered a three-year Memorandum of Understanding (MOU) with Spring Medical Group Ltd. for cannabis cultivation and distribution. CannaPharmaRx will cultivate cannabis at its Cremona Facility in Canada, with Spring purchasing up to 3,000kg for international distribution. Expected revenue from the agreement ranges from $8 million to $12 million, depending on the quantity and timing of orders. Production and delivery are set to start in 2022, securing a reliable revenue stream for CannaPharmaRx as it prepares to launch its operations.
CannaPharmaRx (OTC PINK:CPMD) has signed a genetics transfer agreement with High Profile Cannabis, enhancing its production capabilities. High Profile will supply live cannabis plants and seeds, supporting CannaPharmaRx's application to become a licensed producer in Canada. The agreement, lasting at least 12 months, also includes negotiations for a Supply Agreement for product purchases. CEO Nick Colvin highlighted this partnership as a significant milestone towards revenue generation and expansion plans, with future growth expected across several continents.
CannaPharmaRx, Inc. (OTC PINK:CPMD) announced a Letter of Intent to acquire a cannabis facility in Braman, Oklahoma, comprising 35,000 square feet of cultivation capacity, with an expansion planned to 65,000 square feet by year-end 2022. This facility is expected to generate annual revenue of approximately $21 million, contributing to total projected revenues of $40-$50 million for the company. The acquisition, involving a secured note and transfer of licenses, is set to finalize before March 31, 2022, with first harvest anticipated shortly after closing.
CannaPharmaRx (OTC PINK: CPMD) announced it will cease issuing shares under its S-1 registration, which included 135 million shares filed in May 2021. This decision follows the company's shift towards alternative funding and leasing new facilities, aiming for significant cash flow. CEO Nick Colvin emphasized that discontinuing the S-1 will limit shareholder dilution, which is a critical move for investor confidence. The company is focused on becoming a leader in efficient cannabis production in Canada through advanced facilities and technology.
CannaPharmaRx (OTC PINK: CPMD) has entered into an agreement with a new head grower to enhance their cannabis cultivation capabilities at the Cremona facility, formerly known as the Aurora Mountain facility, which can produce up to 6,000 kg/year. The company expects to complete its first harvest by early Q3 2022, with anticipated annual revenue exceeding $30 million. With EUGMP and GACP certifications, products can be sold in Europe and Israel, marking a significant advancement in CannaPharmaRx's production and distribution strategy.
CannaPharmaRx, Inc. (OTC PINK:CPMD) has announced the hiring of three key personnel to enhance its cannabis production capabilities. Jeremy Metro joins as head grower, bringing extensive cultivation experience, while Jason Buxton serves as quality manager, ensuring product safety and compliance. Rob Osterdal has been appointed head of security, leveraging his management experience at Aurora Cannabis. CEO Nick Colvin stated that these hires aim to expedite product market entry and establish CannaPharmaRx as a leader in the cannabis industry during the current quarter.
CannaPharmaRx (OTC PINK:CPMD) has finalized a 20-year operating lease for the Cremona, Alberta cannabis production facility, previously owned by Aurora Cannabis. This 55,200-square foot facility can produce 6,000 kg/year of cannabis. With plans to obtain EUGMP and GACP certifications, the company aims to enter European and Israeli markets. Expected first harvest and sales are set for Q3 2022, with projected annual revenue surpassing $30 million. CEO Nick Colvin labeled the lease a significant milestone for the company.
CannapharmaRx, Inc. (OTC PINK:CPMD) announced the sale of its Hanover, Ontario facility for $2,000,000 CAD, which spans ten acres and features 48,800 square feet of growing space. The sale was unanimously approved by management to eliminate debt and improve the company's balance sheet. CEO Nick Colvin emphasized that this decision aligns with their strategy to acquire more technologically advanced cannabis production facilities. CannapharmaRx aims to lead in the efficient production of cannabis in Canada through modernization and enhancement of their facilities.
CannaPharmaRx (OTC PINK: CPMD) addressed a press release from an unaffiliated third party that promoted the company without authorization. Management confirmed they did not engage with these groups, highlighting that the promotional statements contained predictions rather than factual information. No significant trading price changes occurred around the promotional activity. The company emphasizes reliance on official SEC filings for accurate information. CannaPharmaRx is developing a 48,500 square foot cannabis grow facility and plans to list on the Canadian Stock Exchange and OTCQB.
CannapharmaRx, Inc. (OTC PINK:CPMD) has signed a formal agreement with K&K Consulting to increase its presence in the Israeli medical cannabis market. The patient count in Israel reached over 60,000 in 2020, but local compliance issues have led to a reliance on imports. This agreement grants CannapharmaRx access to Israeli capital markets, potentially easing financing for its ventures. The company aims to lead in cannabis production by developing state-of-the-art facilities.